Business Wire

Luxembourg Venture Days to Unite Investors, Startups and Innovators on 16 and 17 October 2024

Share

The second edition of the Luxembourg Venture Days will gather investors, startups, and innovators in a joint summit on 16 and 17 October 2024 at Luxexpo The Box. The annual event is organised by Luxembourg’s innovation agency Luxinnovation and the Luxembourg Private Equity and VC Association (LPEA) under the umbrella of Startup Luxembourg, the country’s network to promote its startup ecosystem. This event offers a unique opportunity for investors and startups to convene, exchange, liaise and explore new strategic and investment horizons.

Luxembourg’s stands as a pivotal financial hub offering various services that attract leading investors and markets around the world. It also built a robust, stable, diversified and thriving economy and is home to around 550 startups and 15 incubators, accelerators, and innovation hubs.

The country boasts a dynamic network of business angels, with a growing number of locally managed venture capital funds.

Luxembourg’s position within a 'Greater Region' (comprising bordering territories of France Germany and Belgium) with 12 million inhabitants, its agility and accessibility, coupled with its business-friendly climate, a pragmatic approach, and an easy access to key decision-makers, makes it a hub, bridge, and springboard for investors and startups in strategic and flourishing domains such as, fintech, space, climate, health, logistics, and mobility. It attracts and invites them to participate in shaping an ecosystem with international reach that inspires innovation and fosters sustainable growth.

The growing number of European unicorns (i.e. startups valued at one billion US dollars or more) shows the progress that the European startup ecosystem has made over the past years. Matchmaking platforms and networks that connect startups and investors are key to maintain and further accelerate this momentum. Luxembourg, as an international business hub and gateway at the heart of Europe, is well positioned to stimulate the interaction between investors and entrepreneurs.

“Luxembourg is a hub, bridge, and springboard for investors and startups to explore opportunities and forge partnerships in strategic domains,” says Sasha Baillie, CEO of Luxinnovation. “The Luxembourg Venture Days will bring together several renowned and high-level events under one roof. For startups, it will be an excellent opportunity to pitch in front of a variety of investors. For investors, it will be a place to team up and find new partners and investments. We are proud to join forces with these main actors to develop our new win-win event formula and foster Luxembourg’s role as a vibrant ecosystem, home and hub for startups and investors.”

“Luxembourg is an important hub for private equity and venture capital investors as it provides an agile and accessible platform for established actors and newcomers who want to keep abreast of developments, explore new avenues, grow their investments, and create added value,” adds Stephane Pesch, CEO of LPEA.”

Registration and agenda: Luxembourg Venture Days.

The highlights of Luxembourg Venture Days 2024:

  • Fit 4 Start pitching sessions (16 + 17 October)
    Pitch of 60 pre-selected startups and selection 20 for the next Fit 4 Start edition
  • LPEA annual Insights Conference (17 October)
    Full-day programme with panels and an exclusive pitching event
  • Keynote and masterclasses for investors and startups by US VC Jillian Manus (16 October)
  • Other pitch, demo, networking, and match-making sessions (16 + 17 October)
    • Tomorrow Street matchmaking breakfast with scale-ups (16 October)
    • Gener8tor Demo Day (17 October)
    • Luxembourg Business Angel Network (LBAN) reverse pitch (17 October)
    • Luxembourg Open Innovation Club (LOIC)/ Luxinnovation Reverse Pitch (16 October)
    • 8 pioneering startups to discover (17 October) – Lunch with eight Influential startups embodying our ecosystem’s potential
  • Presentation of the first-ever Dealroom report on EU-backed startups (16 October)
  • Presentation of the report “Titans of Tech” 2024 by European VC GP Bullhound (16 October)
    • Exclusive VC networking dinner (16 October)
  • Insightful panel discussions (16 + 17 October)
    • The value and benefits of investing in women-led startups (17 October)
    • Navigating term sheet negotiations with investors (16 October)
  • General closing ceremony (17 October) –- -Joint-programme for the large audience with:
    • Keynotes by several leading profiles, including Marjut Falkstedt, CEO of the European Investment Fund
    • Roundtable discussions
    • Announcement of the 20 startups selected for Fit 4 Start #15; followed by a networking cocktail.

About Luxinnovation: as the national innovation agency, we empower companies to innovate today to be ready for tomorrow. We contribute to the development of the economy as a whole by identifying innovation opportunities and fostering collaborative innovation projects that stimulate the development of a sustainable, competitive and digital economy. Set up as an Economic Interest Group, Luxinnovation is supported by the Ministry of the Economy, the Ministry for Research and Higher Education, the Ministry of Foreign and European Affairs, the Luxembourg Chamber of Commerce, the Luxembourg Chamber of Skilled Crafts and FEDIL – The Voice of Luxembourg’s Industry. www.luxinnovation.lu

The Luxembourg Private Equity and Venture Capital Association (LPEA) is the most trusted and relevant representative body of private equity and venture capital practitioners with a presence in Luxembourg. Created in 2010 by a leading group of private equity and venture capital players in Luxembourg, with more than 530 members today, LPEA plays a leading role locally actively promoting PE and VC in Luxembourg. LPEA provides a dynamic and interactive platform which helps investors and advisors to navigate through latest trends in the industry. www.lpea.lu

Startup Luxembourg is the unique brand of Luxembourg's startup ecosystem, aiming at showcasing its players and innovators inside and outside the country. This is a public initiative funded by the Ministry of the Economy and managed by Luxinnovation.
www.startupluxembourg.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241004816914/en/

Contacts

Jonas Mercier | Startup Luxembourg Coordinator |jonas.mercier@luxinnovation.lu |
T +352 43 62 63-858
Jean-Michel Gaudron | Head of Content Luxinnovation |
jean-michel.gaudron@luxinnovation.lu | T +352 43 62 63-684

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai

HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release

Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa

Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release

TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi

SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release

On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye